Clinical Trial Update: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating TQB3616 capsules in combination with fulvestrant for advanced HR-positive, HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• TQB3616

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: HR-positive, HER2-negative Advanced Breast Cancer | Phase 2 | Status: COMPLETED